Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
3.75% $29.57
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 823.91 mill |
EPS: | -2.87 |
P/E: | -10.30 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 27.86 mill |
Avg Daily Volume: | 0.118 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.30 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.75x |
Company: PE -10.30 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.866 (-97.07%) $-28.70 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 27.56 - 31.76 ( +/- 7.07%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Dake Benjamin T | Sell | 11 068 | Stock Option (Right to Buy) |
2024-03-27 | Dake Benjamin T | Buy | 11 068 | Common Stock |
2024-03-27 | Dake Benjamin T | Sell | 11 068 | Common Stock |
2024-03-25 | Dake Benjamin T | Sell | 3 432 | Stock Option (Right to Buy) |
2024-03-25 | Dake Benjamin T | Buy | 3 432 | Common Stock |
INSIDER POWER |
---|
45.55 |
Last 100 transactions |
Buy: 747 762 | Sell: 268 911 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $29.57 (3.75% ) |
Volume | 0.215 mill |
Avg. Vol. | 0.118 mill |
% of Avg. Vol | 182.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:30 | buy | $20.81 | N/A | Active |
---|
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.